Xbiome

Xbiome is **China's leading AI-driven microbiome drug development company**. The company is dedicated to gut microbiome using AI techniques, and committed to the gut health of human beings with medical treatments and precise and personalized management. The gut is the largest microbial ecosystem in the human body, hosting about 100 trillion microbes, 500 – 1000 unique species, and containing 150-fold more genes than the human genome, which influence human health systematically. Studies show that **more than 50 human diseases are associated with dysbiosis of gut microbiota**. Unlike the traditional paradigm of drug discovery, Xbiome's approach innovatively combines microbial technologies, artificial intelligence, bioinformatics analysis, and gut microbiome technologies into a unique drug development platform, which substantially speeds up and improves the success rate of new drug development. Founded in **2017**, Xbiome aims to revolutionize the field of gut microbiome drug development by leveraging cutting-edge technologies. Although specific information regarding investment, investors, industries, and headquarters is not available, the company's innovative approach and focus on an emerging field position it as a potential disruptor in the healthcare and biotech industry.